Teriparatide treatment in adult patients with osteogenesis imperfecta type i

Calcified Tissue International

Volumn 93, Issue 5, 2013, Pages 448-452

  Gatti, Davide ^a   Rossini, Maurizio ^a   Viapiana, Ombretta ^a   Povino, Maria Rosaria ^a   Liuzza, Saverio ^a   Fracassi, Elena ^a   Idolazzi, Luca ^a   Adami, Silvano ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

N propeptide of type I collagen; Osteogenesis imperfecta; Sclerostin; Serum dickkopf 1; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; DICKKOPF 1 PROTEIN; NERIDRONIC ACID; PARATHYROID HORMONE[1-34]; PROTEIN P1NP; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; NAUSEA; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOGENESIS IMPERFECTA TYPE I; OSTEOLYSIS; PILOT STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENILE OSTEOPOROSIS; SPINE FRACTURE; TREATMENT DURATION;

ADULT; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HIP; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE;

EID: 84886416032     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-013-9770-2     Document Type: Article

References (23)

1. Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V, Rossini M, Adami S (2003) The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta. J Clin Densitom 6:173-177 (Pubitemid 36693812)
2. Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540-557
3. Cheung MS, Glorieux FH (2008) Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 9:153-160
4. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758-763 (Pubitemid 40571632)
5. Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tatò L (2006) Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149:174-179 (Pubitemid 44128547)
6. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126-130 (Pubitemid 36008347)
7. Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 4:CD005088
8. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300-306 (Pubitemid 43265296)
9. Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S (2004) Bone turnover markers in patients with osteogenesis imperfecta. Bone 34:1013-1016 (Pubitemid 38749238)
10. Girotra M, Rubin MR, Bilezikian JP (2006) The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7:113-121 (Pubitemid 46049523)
11. Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643 (Pubitemid 46984775)
12. Ott SM (2005) Sclerostin and Wnt signaling - the pathway to bone strength. J Clin Endocrinol Metab 90:6741-6743 (Pubitemid 41759344)
13. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577-589 (Pubitemid 32202753)
14. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866-5875
15. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754-766 (Pubitemid 44311706)
16. Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555-1559
17. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50:739-742
18. Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Adami S, Rossini M (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 27:2259-2263
19. Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2010) Institute of Medicine Committee to review dietary reference intakes for vitamin D and calcium dietary reference intakes for calcium and vitamin D. National Academics Press, Washington
20. Rossini M, Gatti D, Adami S (2013) Involvement of wnt/β-catenin signaling in the treatment of osteoporosis Calcif Tissue Int (in press)
21. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
22. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860 (Pubitemid 351398563)
23. Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838-1845